Threshold Pharmaceuticals

Threshold Pharmaceuticals Newswire

Comprehensive Real-Time News Feed for Threshold Pharmaceuticals.

Results 1 - 20 of 73 in Threshold Pharmaceuticals

  1. Merck KGaA, Darmstadt, Germany to Present Data at ASCO That...Read the original story

    Friday May 15 | Canada NewsWire

    ... for evofosfamide in multiple myeloma and melanoma. Evofosfamide is being co-developed with Threshold Pharmaceuticals, Inc. and is currently in Phase III studies for the treatment of soft tissue sarcoma and for pancreatic cancer, as well as in a ...

    Comment?

  2. Merck KGaA, Threshold win fast track for pancreatic cancer drugRead the original story

    Tuesday May 12 | WNFL-AM Green Bay

    Germany's Merck KGaA said that experimental cancer drug evofosfamide, which it is jointly developing with Threshold Pharmaceuticals, won fast track status for the treatment of advanced pancreatic cancer from the U.S. Food and Drug Administration. The drug attacks body tissue that is short of oxygen supply, a typical characteristic of many tumors because cancerous cells often grow without connecting to the blood vessels around them.

    Comment?

  3. Tuesday Pre-Market Insights: THLD, PLL, AOL, CALLRead the original story w/Photo

    Tuesday May 12 | GuruFocus.com

    Threshold Pharmaceuticals, Inc. increased more than 26% in pre-market trading to $4.76 after the pharmaceutical company announced that TH-302 received FDA fast-track designation. The pancreatic cancer drug is being produced in partnership with Merck.

    Comment?

  4. Threshold Pharmaceuticals, Inc.' Partner Merck KGaA, Darmstadt,...Read the original story

    Monday May 11 | BioSpace

    Threshold Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted Fast Track designation to the Company's partner Merck KGaA, Darmstadt, Germany, for the development of evofosfamide , administered in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer. This is the second Fast Track designation for evofosfamide, the first having been granted to Threshold in November 2014 for the development of evofosfamide in combination with doxorubicin for the treatment of patients with advanced soft tissue sarcoma.

    Comment?

  5. Threshold Pharmaceuticals (THLD) Stock Soars on FDA Fast Track DesignationRead the original story w/Photo

    Tuesday May 12 | TheStreet.com

    ... and Development for the biopharmaceutical business, Luciano Rossetti. TheStreet Ratings team rates THRESHOLD PHARMACEUTICALS as a Sell with a ratings score of E+. TheStreet Ratings Team has this to say about their recommendation: "We rate THRESHOLD ...

    Comment?

  6. Merck KGaA, Darmstadt, Germany granted FDA Fast Track designation for development of evofosfamideRead the original story w/Photo

    Tuesday May 12 | Medical News

    ... tumors. The compound, currently in Phase III trials, is being developed in collaboration with Threshold Pharmaceuticals, Inc. "Merck KGaA, Darmstadt, Germany, is focused on discovering and developing innovative new therapeutic options for cancers ...

    Comment?

  7. Merck KGaA, Darmstadt, Germany, Receives FDA Fast Track Designation...Read the original story

    Monday May 11 | BioSpace

    ... tumors. The compound, currently in Phase III trials, is being developed in collaboration with Threshold Pharmaceuticals, Inc. . "Many patients with pancreatic cancer present with advanced, inoperable tumors, and there are limited treatment options ...

    Comment?

  8. Merck Receives FDA Fast Track Designation for Evofosfamide for...Read the original story

    Tuesday May 12 | Sys-Con Media

    ... tumors. The compound, currently in Phase III trials, is being developed in collaboration with Threshold Pharmaceuticals, Inc. Merck over the past years has bolstered its growth platforms in healthcare, life science and performance materials to ...

    Comment?

  9. Threshold Pharmaceuticals Announces Presentation and Webcast at the...Read the original story

    Monday May 11 | Freshnews

    05/11/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the 2015 UBS Global Healthcare Conference on May 19, 2015, at 3:30 p.m. ...

    Comment?

  10. Tocagen Adds Venture Capitalist To BoardRead the original story

    Tuesday May 5 | SocalTECH.com

    ... Investigational Drug Branch at the National Cancer Institute. Parkinson also is on the boards of Threshold Pharmaceuticals and Cerulean Pharma Inc. and had previously been on the boards of Facet Biotech and Ambit Biosciences Corporation, before both ...

    Comment?

  11. "Angiosarcoma Global Clinical Trials Review, H1, 2015" PublishedRead the original story

    Saturday May 2 | PR-inside.com

    ... 27 Prominent Drugs 28 Clinical Trial Profiles 29 Clinical Trial Overview of Top Companies 29 Threshold Pharmaceuticals, Inc. 29 Clinical Trial Overview of Threshold Pharmaceuticals, Inc. 29 Bayer AG 30 Clinical Trial Overview of Bayer AG 30 Merck & ...

    Comment?

  12. Synovial Sarcoma Global Clinical Trials Review, H1, 2015 - New Study ReleasedRead the original story

    Friday May 1 | PR-inside.com

    ... Companies 31 F. Hoffmann-La Roche Ltd. 31 Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 31 Threshold Pharmaceuticals, Inc. 32 Clinical Trial Overview of Threshold Pharmaceuticals, Inc. 32 EpiZyme, Inc. 33 Clinical Trial Overview of EpiZyme, ...

    Comment?

  13. Threshold Pharmaceuticals Reports First Quarter 2015 Financial and Operational ResultsRead the original story

    Thursday Apr 30 | Freshnews

    04/30/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today reported financial results for the first quarter 2015. Revenue for the first quarter ended March 31, 2015 was $3.7 million. The operating loss for the first quarter ended March 31, 2015 ...

    Comment?

  14. Threshold Pharmaceuticals, Inc. Reports Preclinical Data Suggesting...Read the original story

    Wednesday Apr 22 | BioSpace

    Threshold Pharmaceuticals, Inc. today announced preclinical data on TH-4000, its proprietary, molecularly-targeted, hypoxia-activated, irreversible epidermal growth factor receptor tyrosine kinase inhibitor suggesting that TH-4000 may overcome resistance to therapy with conventional EGFR-TKIs. In a xenograft model of non-small cell lung cancer in which both wild-type EGFR and mutant EGFR are present , TH-4000 was more active than the conventional EGFR-TKI erlotinib.

    Comment?

  15. Human clinical trials planned for new anti-cancer compoundRead the original story

    Wednesday Apr 22 | Scoop

    After 10 years of discovery and research, two University of Auckland medical oncology researchers along with their dedicated teams have developed a new anti-cancer compound that will advance to human phase two clinical trials. The co-inventors of the compound TH-4000, Dr Adam Patterson and Dr Jeff Smaill, senior academics from the Auckland Cancer Society Research Centre and the Maurice Wilkins Centre, have collaborated with a NASDAQ-listed American bio-technology company, Threshold Pharmaceuticals, to advance the compound to this stage.

    Comment?

  16. Kiwi cancer drug rescuedRead the original story w/Photo

    Wednesday Apr 22 | The New Zealand Herald

    ... for the types of cancer they hoped to target in further trials. However a new sponsor, US company Threshold Pharmaceuticals, soon picked up TH-4000. It had been a roller-coaster ride, but the drug was now with the world's leading biotechnology ...

    Comment?

  17. NeuroVive: Development Of NVP014 For The Treatment Of Stroke Enters New Phase In Collaboration WithRead the original story

    Apr 16, 2015 | BioSpace

    Threshold Pharmaceuticals, Inc. , today announced that it will host an Analyst and Investor Day on Friday, April 24, 2015, from 11:30 AM to 1:30 PM Eastern Time in New York City. Members of Threshold's senior management team will be joined by other research and clinical leaders in the field of tumor hypoxia, hypoxia-activated prodrugs, and next-generation epidermal growth factor receptor tyrosine kinase inhibitor therapy to discuss its clinical development programs for evofosfamide and TH-4000.

    Comment?

  18. Threshold Pharmaceuticals to Host Analyst and Investor Day on April 24 in New York CityRead the original story w/Photo

    Apr 16, 2015 | Market Wire

    Members of Threshold's senior management team will be joined by other research and clinical leaders in the field of tumor hypoxia, hypoxia-activated prodrugs, and next-generation epidermal growth factor receptor tyrosine kinase inhibitor therapy to discuss its clinical development programs for evofosfamide and TH-4000. Guest speakers scheduled to give presentations at this event include Stephen V. Liu, M.D., Assistant Professor of Medicine, Georgetown University Medical Center; Adam Patterson, Ph.D., Head of Translational Therapeutics, University of Auckland, New Zealand; and Jeff Smaill, Ph.D., Senior Medicinal Chemist, University of Auckland, New Zealand.

    Comment?

  19. "Myelofibrosis - Pipeline Review, H1 2015" now available at Fast Market ResearchRead the original story

    Mar 28, 2015 | PR-inside.com

    ... Inc., Pfizer Inc., PharmaEssentia Corporation, Promedior, Inc., Stemline Therapeutics, Inc., Threshold Pharmaceuticals, Inc. About Global Markets Direct Global Markets Direct is a leading provider of global business intelligence and market analysis. ...

    Comment?

  20. Threshold Pharmaceuticals, Inc. To Present Data Supporting Planned...Read the original story

    Mar 18, 2015 | BioSpace

    Threshold Pharmaceuticals, Inc. , today announced it will present data on its investigational anti-cancer drugs at the annual meeting of the American Association for Cancer Research 2015 being held April 18-22, 2015, in Philadelphia, Pennsylvania. The company will present clinical and preclinical data on TH-4000, its proprietary, hypoxia-activated irreversible epidermal growth factor receptor tyrosine kinase inhibitor , which the company believes support its two planned Phase 2 proof-of-concept clinical trials of TH-4000.

    Comment?